NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $460,102 | -46.8% | 18,100 | -24.4% | 0.00% | -50.0% |
| Q1 2023 | $864,924 | +25.4% | 23,926 | +37.4% | 0.01% | +33.3% |
| Q4 2022 | $689,476 | -80.6% | 17,411 | -18.8% | 0.01% | -84.2% |
| Q2 2021 | $3,556,000 | +612.6% | 21,449 | +329.8% | 0.04% | +22.6% |
| Q1 2020 | $499,000 | +101.2% | 4,991 | +135.9% | 0.03% | +416.7% |
| Q4 2019 | $248,000 | -28.7% | 2,116 | -65.3% | 0.01% | -60.0% |
| Q3 2018 | $348,000 | -12.8% | 6,100 | +22.0% | 0.02% | -31.8% |
| Q2 2018 | $399,000 | -77.0% | 5,000 | -75.0% | 0.02% | -83.1% |
| Q1 2018 | $1,734,000 | -46.0% | 20,008 | -57.0% | 0.13% | -50.6% |
| Q4 2017 | $3,214,000 | +892.0% | 46,555 | +1207.7% | 0.26% | +776.7% |
| Q3 2017 | $324,000 | -79.2% | 3,560 | -83.0% | 0.03% | -81.2% |
| Q2 2017 | $1,556,000 | -53.5% | 20,906 | -54.6% | 0.16% | -63.0% |
| Q4 2016 | $3,345,000 | +1335.6% | 46,033 | +1966.1% | 0.43% | +982.5% |
| Q3 2016 | $233,000 | -38.7% | 2,228 | -67.0% | 0.04% | -74.2% |
| Q1 2016 | $380,000 | – | 6,742 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |